Pharma Marketers Grapple With Trump-Era Regulatory Whiplash

In the midst of mounting political scrutiny and regulatory ambiguity, pharmaceutical marketers are navigating one of the most uncertain environments in recent memory.

The MAHA (Make America Healthy Again) movement, with Trump-era regulatory curveballs and skepticism fueled by Secretary of Health and Human Services Robert F. Kennedy Jr., is reshaping the rules of pharma marketing.

At Advertising Week New York, industry leaders described how shifting signals from the Trump administration, paired with growing public mistrust of Big Pharma, are forcing brands to rethink how they communicate with consumers.

The session, Driving Innovation and Creativity in Highly Regulated Categories, brought together Kim Wijkstrom, CMO of Vanda Pharmaceuticals; Kimberly Jones, president and CEO of Butler/Till; and Laurence Richards, healthcare marketing executive at CultHealth, moderated by Kempner Communications founder Katie Kempner.

Though the panel covered broad creative strategies, conversation repeatedly returned to regulatory confusion and the downstream marketing consequences.

“Needless to say, we’ve been writing a lot of field leads. We seem to be updating them daily, because there’s always some new tidbit in the news,” said Jones. “A lot of our healthcare clients are certainly on edge about any potential regulations that might be forthcoming.”

Recent months have seen the White House link widely trusted products such as vaccines and Tylenol use in pregnancy to autism, signaling new FDA label changes and issuing physician advisories despite a lack of scientific consensus.

Those moves, coupled with pronouncements from President Trump and RFK Jr., have amplified public mistrust in mainstream medicine and injected fresh uncertainty into how pharmaceutical advertising will be regulated.

Richards described the fallout from a recent White House memo on direct-to-consumer pharmaceutical advertising.

“What the administration has done [with] the regulation is confuse everyone,” he said. “They scared the living crap out of every single company.”

Wijkstrom echoed that reaction from the brand side: “We were frankly confused by it. It wasn’t very clear, and we have been reviewing legal agents right now, given the kind of hoops we have to jump through from a regulatory perspective to get anything approved.”